Treating low-risk myelodysplastic syndromes in the community setting
Cripe, L.D.
Clinical Advances in Hematology and Oncology H&o 6(6): 418-420
2008
ISSN/ISBN: 1543-0790 PMID: 18567986 Document Number: 616402
Document emailed within 1 workday
Related Documents
Greenberg, P.L.; Sanz, G.F.; Sanz, M.A. 1999: Prognostic scoring systems for risk assessment in myelodysplastic syndromes Forum 9(1): 17-31Sanz, G.F.; Sanz, M.A. 1999: Progress in intensive chemotherapy for high-risk myelodysplastic syndromes Forum 9(1): 63-71
Invernizzi, R.; Pecci, A.; Rossi, G.; Pelizzari, A.M.; Giusto, M.; Tinelli, C.; Ascari, E. 1997: Idarubicin and cytosine arabinoside in the induction and maintenance therapy of high-risk myelodysplastic syndromes Haematologica 82(6): 660-663
Liu, H.; He, G.-s.; Wu, D.-p.; Sun, A.-n.; Shao, Z.-h.; Qian, S.-x.; Xiao, Z.-j.; Ma, J.; Wang, S.-y.; Xu, X.-p.; Liu, T.; Jin, J.; Chen, Z.-c.; Fang, M.-y.; Chen, B.-a.; Xu, L.-p.; Shen, Z.-x.; Ruan, C.-g. 2012: Clinical efficacies and safety of HAG regimen for patients with high-risk myelodysplastic syndromes: a multicentre study Zhonghua Yi Xue Za Zhi 92(10): 689-691
Maiolo, A.T.; Cortelezzi, A.; Calori, R.; Polli, E.E. 1990: Recombinant gamma-interferon as first line therapy for high risk myelodysplastic syndromes. Italian MDS Study Group Leukemia 4(7): 480-485
Tassin, F.; Hermanne, J.P.; Schaaf-Lafontaine, N.; Herens, C.; Thiry, A.; Paulus, J.M.; Boniver, J.; Fillet, G. 1998: Myelodysplastic syndromes: preleukemic syndromes Revue Medicale de Liege 53(6): 357-362
Guisasola Zulueta, M.C.; Gilsanz Fernández, C.; Tintó del Val, J.A.; García de la Fuente, A. 1986: Myelodysplastic syndromes Revista Clinica Espanola 179(4): 190-195
Dusek, J.; Bednár, B.; Dorazilová, V.; Fakan, F.; Kerekes, Z. 1990: Myelodysplastic syndromes Ceskoslovenska Patologie 26(3): 129-134
Strebel, U. 1988: Myelodysplastic syndromes Therapeutische Umschau. Revue Therapeutique 45(2): 100-105
Lishner, M.; Ravid, M. 1988: Myelodysplastic syndromes Harefuah 115(3-4): 73-76
Sizoo, W.; Hagenbeek, A.; Löwenberg, B.; van 't Veer, M.B.; Sintnicolaas, K. 1987: Myelodysplastic syndromes Nederlands Tijdschrift Voor Geneeskunde 131(38): 1658-1661
Solary, E.; Fontenay, M.ël. 2010: Myeloproliferative/myelodysplastic syndromes La Revue du Praticien 60(10): 1413-1415
Carvajal Méndez, I.; García Vadillo, J.A.; Herranz Varela, A.; González Alvaro, I.; Casado Montero, F.; Castañeda Sanz, S. 1996: Polyarthritis associated with myelodysplastic syndromes Revista Clinica Espanola 196(8): 539-541
Tohyama, K. 2012: Treatment of myelodysplastic syndromes (MDS) Nihon Rinsho. Japanese Journal of Clinical Medicine 70(Suppl 2): 367-372
Doll, D.C.; List, A.F. 1992: Myelodysplastic syndromes: introduction Seminars in Oncology 19(1): 1-3
Turtureanu-Hanganu, E. 2004: The point on myelodysplastic syndromes Revista Medico-Chirurgicala a Societatii de Medici Si Naturalisti Din Iasi 108(1): 9-16
Hellström-Lindberg, E. 1999: Treatment of adult myelodysplastic syndromes International Journal of Hematology 70(3): 141-154
Kim, H.; Garcia-Manero, G. 2008: Management of myelodysplastic syndromes: just the beginning Oncology 22(12): 1360; 1363, 1368
Aviles, A.; García, L.D.; Romero, N.; Tripp, F.; González-Llaven, J. 1988: Treatment of myelodysplastic syndromes with danazol Archivos de Investigacion Medica 19(1): 73-77
Peskin, S.R. 2009: Myelodysplastic syndromes (MDS): the current landscape Managed Care 18(11 Suppl 9: 2-3